Efficacy and safety of baricitinib in hospitalized adults with severe or critical covid-19 (bari-solidact): a randomised, double-blind, placebo-controlled phase 3 trial

HIGHLIGHTS

• who: Marius Tru00f8seid from the (UNIVERSITY) have published the research: Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial, in the Journal: (JOURNAL) of May/18,/2021
• what: The aim was to evaluate the effect of baricitinib vs. placebo, given in addition to SoC, on the occurrence of death within 60 days.
• how: The trial was conducted in accordance with ICH E6 (R2) Good Clinical Practice and the ethical principles of the Declaration of Helsinki.

 

If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.